证券代码：003007 证券简称：直真科技 公告编号：2025-042 北京直真科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 北京直真科技股份有限公司（以下简称"公司"）第五届董事会第二十三次会议于 知时限，会议通知已于2025年6月12日以电话、口头方式发出。 本次会议应出席董事9人，实际出席董事9人。会议由公司董事长袁隽召集并主持， 公司部分监事、高级管理人员列席了会议。本次会议的召集及召开程序符合《中华人民 共和国公司法》等法律法规、规范性文件及《公司章程》的有关规定。 二、董事会会议审议情况 经全体董事认真审议，通过了以下议案： （一）审议通过《关于豁免本次董事会通知程序要求的议案》。 为提高决策效率，全体董事一致同意豁免本次会议通知时限。 表决结果：9票同意，0 票反对，0 票弃权。 （二）审议通过《关于延长公司2024年度向特定对象发行A股股票股东大会决议有效 期的议案》。 公司控股股东王飞雪、金建林、袁隽于2025年6月12日向董事会发出《关于提议增加 对象发行A股股票股东大会决议有效期的议案》提交至2 ...

Core Viewpoint - Ningxia Yinglite Chemical Co., Ltd. has faced continuous losses in 2024 and the first quarter of 2025, primarily due to low prices of its main products, PVC and E-PVC, which have negatively impacted its financial performance [1][3]. Financial Performance Summary - The company's operating revenue for 2024 was CNY 400.12 million, a decrease of 2.32% year-on-year, while the operating cost was CNY 436.25 million, down 1.43% year-on-year [2]. - The gross profit margin was negative CNY 36.13 million, reflecting a decline of 9.68% year-on-year, indicating significant operational challenges [2]. - The net profit attributable to shareholders was negative CNY 82.24 million, representing a year-on-year increase in losses of 17.75% [2][3]. - The company reported a net profit after deducting non-recurring gains and losses of negative CNY 85.05 million, with a year-on-year increase in losses of 21.17% [2]. Operational Insights - The company’s main business includes the production and sales of calcium carbide, polyvinyl chloride (PVC), caustic soda, hydrochloric acid, and liquid chlorine, with a stable customer base and a flexible production plan [4]. - The operational model emphasizes a structured procurement strategy and production planning that adapts to market changes, ensuring a stable supply of raw materials [4]. Future Outlook - Despite the reported losses, the company asserts that these will not significantly impact its operational capabilities or the ongoing projects funded by the recent stock issuance [5]. - The total amount raised from the stock issuance is expected to be no more than CNY 700 million, aimed at enhancing the integrated industrial chain and improving profitability [5]. Compliance and Governance - The company has confirmed that it meets the conditions for issuing shares to specific investors, with no significant adverse impacts from recent financial performance on the issuance process [6][7].

Meeting Overview - The fourth board meeting of Shenzhen Zhenyou Technology Co., Ltd. was held on June 12, 2025, with all 8 directors present, ensuring compliance with relevant laws and regulations [1][2]. A-Share Issuance Proposal - The board approved the proposal for the company to issue A-shares to specific investors, confirming that the company meets the necessary qualifications and conditions [2][3]. - The proposal for the 2025 A-share issuance plan was also approved, with a unanimous vote of 8 in favor [2][3]. Issuance Details - The A-shares will be issued at a par value of 1.00 yuan each, with a maximum of 35 specific investors eligible to participate, including various financial institutions and qualified investors [3][4]. - The pricing mechanism will be based on the average trading price of the company's A-shares over the 20 trading days prior to the pricing date, set at no less than 80% of this average [4][5]. Fundraising and Investment Plans - The total amount to be raised from this issuance is capped at 1,069 million yuan, which will be allocated entirely to the research and industrialization of satellite internet communication products [6][7]. - The company may adjust the investment sequence and amounts based on project progress and funding needs, with the option to use self-raised funds prior to the official fundraising [7][8]. Share Transfer Restrictions - Shares acquired through this issuance will be subject to a six-month transfer restriction post-issuance, with further restrictions applicable to shares obtained through stock dividends or capital increases [8][9]. Authorization and Governance - The board proposed to authorize itself and its designated representatives to handle all matters related to the issuance, including adjustments to the plan as necessary [14][15]. - A third extraordinary shareholders' meeting is scheduled for June 30, 2025, to further discuss and approve the issuance plan [15].

Core Viewpoint - The company plans to issue A-shares to specific investors, which may dilute immediate returns, and has proposed measures to compensate for this dilution [1][6][12] Financial Impact Analysis - The company conducted a hypothetical analysis of the impact of the share issuance on key financial metrics, which does not constitute a profit forecast [2][3] - The analysis includes three scenarios for the company's net profit in 2025 compared to adjusted 2024 figures, with potential declines or increases of 30% [2][4] - Key financial metrics before and after the issuance are provided, showing changes in net profit and earnings per share [4][5] Issuance Necessity and Reasonableness - The funds raised will be used for projects related to ecological restoration, landscape enhancement, and innovation in grass technology, aligning with the company's core business [6][12] - The issuance is deemed necessary to enhance the company's competitive position and market share [7][12] Project Implementation and Resource Readiness - The company has established a comprehensive talent structure and technical reserves to ensure the successful implementation of the fundraising projects [7][10] - The company has a strong research and innovation capability, with numerous patents and a data platform to support ecological restoration efforts [9][10] Measures to Mitigate Dilution of Immediate Returns - The company will strengthen fundraising management and ensure funds are used appropriately [10][11] - Efforts will be made to expand market reach and select high-quality projects to improve net profit levels [11][12] - The company plans to enhance governance and financial management to optimize shareholder returns [13][14] Commitments from Management and Major Shareholders - All directors and senior management have committed to ensuring the effectiveness of the compensation measures for diluted returns [15][16] - The controlling shareholder has also made commitments to uphold the interests of the company and its investors [15][16]

Core Viewpoint - The company has approved a plan to issue A-shares to specific investors, aiming to raise up to RMB 149,500 million for various projects, subject to shareholder approval and regulatory compliance [1][2][3]. Group 1: Meeting Details - The fifth supervisory board meeting was held on June 11, 2025, with all three supervisors present, confirming compliance with relevant laws and regulations [1]. - The meeting passed several resolutions, including the approval of the company's eligibility to issue A-shares to specific investors [2]. Group 2: Issuance Plan - The company plans to issue domestic A-shares with a par value of RMB 1.00 each, targeting no more than 35 specific investors, including various financial institutions [2][3]. - The issuance will occur after obtaining approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission [3]. Group 3: Fundraising and Use of Proceeds - The total amount to be raised is capped at RMB 149,500 million, which will be allocated to specific projects with a total investment of RMB 200,393.79 million [6]. - If the actual net amount raised is less than the funding needs, the board may adjust the allocation of funds while maintaining the project's integrity [6]. Group 4: Shareholder and Regulatory Compliance - The shares subscribed by the investors will be subject to a six-month lock-up period post-issuance [6]. - The company will establish a special account for managing the raised funds, ensuring compliance with relevant regulations [11]. Group 5: Future Plans and Commitments - The company has prepared a three-year shareholder return plan to enhance transparency and encourage long-term investment [10]. - The board has committed to measures to mitigate the dilution of immediate returns for existing shareholders due to the new issuance [9].

Meeting Information - The company will hold its third extraordinary general meeting of shareholders on June 30, 2025, at 15:00 in Hohhot City [1][2] - Shareholders can participate through on-site voting or online voting, with specific time slots for online voting provided [2][10] Voting Procedures - Shareholders must register to attend the meeting, with specific requirements for both corporate and individual shareholders outlined [6] - The voting process includes options for agreeing, opposing, or abstaining from proposals, with rules for handling duplicate votes [10][14] Agenda Items - The meeting will discuss several proposals, including the issuance of A-shares to specific targets and related feasibility reports [3][5] - Proposals require different levels of approval, with special resolutions needing two-thirds majority and ordinary resolutions needing a simple majority [5][6] Special Considerations - The meeting will separately count votes from minority investors, defined as those not holding more than 5% of shares [6] - The company will provide detailed documentation regarding the proposals on the designated information disclosure website [5][6]

证券代码：600601 证券简称：方正科技 公告编号：临 2025-028 方正科技集团股份有限公司 关于 2025 年度向特定对象发行 A 股股票摊薄即期 回报、采取填补措施及相关主体承诺的公告 （一）主要假设前提 有发生重大变化。 仅用于计算本次发行摊薄即期回报对公司主要指标的影响，不构成对本次发行实 际完成时间的判断或承诺，最终发行完成以上海证券交易所审核通过且经中国证 监会同意注册后实际发行完成时间为准。 设本次向特定对象发行股票的发行数量为 1,251,087,986 股，假设本次发行募集 资金总额为 198,000 万元（不考虑发行费用），不考虑其他因素导致股本发生变 化的情况。 性损益后归属于母公司股东的净利润为 21,019.41 万元。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 方正科技集团股份有限公司（以下简称"方正科技"或"公司"）于 2025 年 6 月 10 日召开第十三届董事会 2025 年第三次会议和第十三届监事会 2025 年 第三次会议，审议通过了公司关于 2025 年度向特定对象发行 ...

Core Viewpoint - Brother Technology Co., Ltd. is planning to issue A-shares to specific investors to raise funds primarily for expanding its production capacity of iodinated contrast agents, specifically increasing the production capacity of iodinated raw materials from 100 tons to 700 tons, with a total investment of approximately 69 million yuan for the project [1][9]. Group 1: Financial Overview - The company reported revenues of 3.41 billion yuan, 2.82 billion yuan, and a loss in 2023 due to declining prices of chromium salt products, which affected both revenue and gross margin [1][2]. - The gross margin for the main business was 24.83%, 10.40%, and 14.63% over the reporting periods, indicating significant fluctuations influenced by market conditions and raw material prices [4][5]. Group 2: Investment and Project Details - The funds raised will be allocated to construction, equipment purchase, and installation, leading to increased fixed asset depreciation and intangible asset amortization, which will raise operational costs [1][3]. - The project aims to achieve an annual production capacity of 600 tons of iodinated raw materials, with the feasibility of the project assessed based on market demand and competition [1][6]. Group 3: Risks and Challenges - There are risks associated with the inability to absorb the new production capacity if market demand does not meet expectations, potentially leading to excess capacity and increased competition [1][2]. - The company faces uncertainties regarding the economic benefits of previous fundraising projects, particularly if market conditions or regulatory environments change adversely [2][3]. - The company must navigate the complexities of regulatory approvals for its iodinated contrast agents, which could impact market entry and expected returns [5][6]. Group 4: Share Structure and Ownership - As of December 31, 2024, the company's total share capital is 106,370.05 million yuan, with 34.05% held as restricted shares and 65.95% as unrestricted shares [14]. - The top ten shareholders collectively hold 47.58% of the shares, indicating a diverse ownership structure [14].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688301 证券简称：奕瑞科技 公告编号：2025-037 转债代码：118025 转债简称：奕瑞转债 奕瑞电子科技集团股份有限公司 关于实施2024年年度权益分派时可转债转股 价格调整暨转股连续停牌的提示性公告 本次权益分派方案实施后，公司将依据《上海奕瑞光电子科技股份有限公司向不特定对象发行可转换公 司债券募集说明书》中所载的发行条款及相关规定，对"奕瑞转债"当期转股价格进行调整。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 证券停复牌情况：适用 因实施2024年年度权益分派，奕瑞电子科技集团股份有限公司（以下简称"公司"）的相关证券停复牌情 况如下：权益分派公告日前一交易日（2025年6月12日）至权益分派股权登记日期间，公司可转债将停 止转股。 ■ 注：停牌终止日及复牌日可在本公司后续发布的可转债转股价格调整公告中查阅。 一、2024年年度权益分派方案的基本情况 公司2024年年度利润分配方案为：公司2024年年度拟以实施权益分派股权 ...

证券代码：688520 证券简称：神州细胞 公告编号：2025-022 北京神州细胞生物技术集团股份公司 第三届董事会第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 北京神州细胞生物技术集团股份公司（以下简称"公司"）第三届董事会第二 次会议于 2025 年 6 月 5 日在公司会议室以现场及通讯方式召开，本次会议的通 知及相关材料于 2025 年 5 月 30 日送达全体董事。本次会议应出席董事 7 人，实 际到会董事 7 人。本次会议由董事长谢良志先生主持，会议的召集和召开程序符 合《中华人民共和国公司法》《北京神州细胞生物技术集团股份公司章程》（以 下简称"《公司章程》"）以及其他有关法律法规、规范性文件的规定。 二、董事会会议审议情况 经与会董事充分讨论，会议以投票表决方式审议通过了如下议案： （一）审议通过《关于公司符合向特定对象发行 A 股股票条件的议案》 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司证券 发行注册管理办法》等有关法律法规和规范性文件 ...